Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric <font color="red">treatment_1</font> <font color="red">of_1</font> <font color="red">acute_2</font> <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> <font color="red">in_2</font> <font color="red">children_2</font> <font color="red">._2</font> <font color="red">
<br>
<br>_1</font> BACKGROUND <font color="red">Acute_2</font> <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> is a potentially serious condition in <font color="red">children_1</font> <font color="red">._1</font> Because of the increasing resistance of enteric pathogens to commonly used oral antibiotics , intramuscular ceftriaxone has become the routine drug in the treatment of <font color="red">acute_2</font> <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> requiring an emergency visit in southern Israel . The inconvenience of this parenteral regimen created an increased need for oral pediatric formulations for the treatment of <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> <font color="red">._2</font> 
<br> OBJECTIVES To evaluate the efficacy and safety of a suspension formulation of ciprofloxacin in the treatment of <font color="red">acute_2</font> <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> <font color="red">in_2</font> <font color="red">infants_2</font> <font color="red">and_2</font> <font color="red">children_2</font> <font color="red">._2</font> 
<br> PATIENTS AND METHODS <font color="red">From_2</font> <font color="red">July_2</font> <font color="red">1996_2</font> <font color="red">through_2</font> <font color="red">December_2</font> <font color="red">1997_2</font> <font color="red">,_2</font> <font color="red">201_2</font> <font color="red">evaluable_2</font> <font color="red">children_2</font> <font color="red">ages_2</font> <font color="red">6_2</font> <font color="red">months_2</font> <font color="red">to_2</font> <font color="red">10_2</font> <font color="red">years_2</font> <font color="red">(_2</font> <font color="red">35%_2</font> <font color="red"><_2</font> <font color="red">1_2</font> <font color="red">year_2</font> <font color="red">;_2</font> <font color="red">70%_2</font> <font color="red"><3_2</font> <font color="red">years_2</font> <font color="red">)_2</font> <font color="red">presenting_2</font> <font color="red">with_2</font> <font color="red">acute_2</font> <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> <font color="red">at_2</font> <font color="red">the_2</font> <font color="red">Pediatric_2</font> <font color="red">Emergency_2</font> <font color="red">Room_2</font> were randomized to receive either ciprofloxacin suspension ( 10 mg / kg twice a day + i m placebo ; n = 95 ) or i m ceftriaxone ( 50 mg / kg / day + placebo suspension ; n = 106 ) for 3 days in a double blind manner . Stool cultures for Shigella , Salmonella , Campylobacter spp . and diarrheagenic Escherichia coli were obtained on Days 1 , 3 , 4 to 5 and 21 + /- 5 . Clinical response and safety were assessed on Days 1 , 2 , 3 , 4 to 5 and 21 + /- 5 . 
<br> RESULTS We isolated 127 pathogens from 121 ( 60% ) patients : 73 ( 57% ) Shigella ; 23 ( 18% ) Salmonella ; 18 ( 14% ) E. coli ; and 13 ( 10% ) Campylobacter . Overall bacteriologic eradication on Day 4 to 5 was 99% for Shigella , 77% for Salmonella and 77% for Campylobacter , with no difference between the 2 groups . Clinical cure or improvement was observed in 100 and 99% of the ciprofloxacin and ceftriaxone groups , respectively . Serum ciprofloxacin values determined on Day 3 of the treatment were higher in the majority of patients than were the MIC50 and MIC90 values for the Shigella and Salmonella spp . isolated . Possible drug - related adverse events occurred in 13 patients [ ciprofloxacin , 8 ( 8% ) ; ceftriaxone , 5 ( 4.7% ) ] and were mild and transient . Joint examination was normal during and after completion of therapy in all patients . 
<br> CONCLUSION Oral ciprofloxacin was as safe and effective as intramuscular ceftriaxone for the empiric treatment of <font color="red">acute_2</font> <font color="red">invasive_2</font> <font color="red">diarrhea_2</font> <font color="red">in_2</font> <font color="red">ambulatory_2</font> <font color="red">pediatric_2</font> <font color="red">patients_2</font> <font color="red">requiring_2</font> <font color="red">an_2</font> <font color="red">emergency_2</font> <font color="red">room_2</font> <font color="red">visit_2</font> <font color="red">._2</font>